The company submitted the Monitoring Agency Report for the Quarter ended 30th June, 2026.

:t lPOLYMED Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi -110 020 (INDIA) T: +91-11-33550700, 47317000 E: info@polymedicure.com W: polymedicure.com CIN: L 40300DL 1995PLC066923 Date: 10.08.2026 Scrip Code: -531768 Scrip Code:- POL YMED The Manager, The Manager BSE Limited, National Stock Exchange of India Limited Department of Corporate Services, Exchange Plaza, Plot No. C/1-Block-G Phirozee Jeejeebhoy Towers, Bandra Kurla Complex, Bandra(E), Dalal Street, Mumbai- 400001. Mumbai-400051. Subject: - Monitoring Agency Report for the quarter ended 30th June, 2026 Dear Sir/ Madam, Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith the Monitoring Agency Report dated 10th August, 2026, for the quarter ended 30th June 2026, issued by CRISIL Ratings Limited, the Monitoring Agency appointed to monitor utilization of proceeds of the qualified institutions placement' issue. Kindly take the information on record. Thanking you For Poly Medicure Limited Av inash Chandra Company Secretary M. No. A32270 Encl. as above Plants: Plot No.l 04-105 & 115-116-117, Sector-59, HSIIDC Industrial Area, Ballabgarh, Faridabad -121004, Haryana (INDIA) Plot No. 33-34, Sector-68, IMT. Faridabad-121004, (Haryana) INDIA T: +91-129-4287000, 3355070 Monitoring Agency Report Poly Medicure Limited for the quarter ended June 30, 2026 CRL/MAR/POLML/2026-27/1880 August 10, 2026 Poly Medicure Limited 232B, 3rd Floor, Okhla Industrial Estate, Phase III New Delhi 110 020, India Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Qualified Institutional Placement (“QIP”) of Poly Medicure Limited (“the Company”) Pursuant to Regulation 173A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated August 17, 2024, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of QIP for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Poly Medicure Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Poly Medicure Limited Names of the promoter: Mr. Mukulika Baid Mr. Jugal Kishore Baid Mr. Bhupendra Raj Mehta Mr. Rishi Baid Mr. Vishal Baid Mr. Himanshu Baid Industry/sector to which it belongs: Medical Equipment & Supplies 2) Issue Details Issue Period: August 19, 2024, to August 22, 2024 Type of issue (public/rights): Qualified Institutional Placement (QIP) Type of specified securities: Equity Shares QIP Grading, if any: NA Issue size: Rs 99,999.98 lakh (Net proceeds of Rs 98,534.37 lakh*) *Crisil Ratings shall be monitoring the net proceeds amount. During the quarter ended March 31, 2025, Net proceeds amount was revised from Rs. 98,499.98 lakhs to Rs. 98,534.37 lakh, owing to issue expenses being lower by Rs. 34.39 lakh. Same was added to GCP and consequently GCP amount changed from Rs. 23,499.98 lakh to Rs. 23,534.37 lakh. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ certifications Comments of the Comments considered by Particulars Reply Monitoring of the Board Monitoring Agency of Directors Agency for preparation of report Statutory Auditors Certificate^, Proceeds were Management utilized towards undertaking, capital Placement expenditure as in Whether all utilization is as per the disclosures No Yes Document August line with the in the Offer Document? Comments 22, 2024 disclosures (hereinafter provided in the referred as “Offer Placement Document”), Bank Document Statements Source of information/ certifications Comments of the Comments considered by Particulars Reply Monitoring of the Board Monitoring Agency of Directors Agency for preparation of report Whether shareholder approval has been obtained in case of material deviations from NA No Comments Comments expenditures disclosed in the Offer Document? Whether the means of finance for the disclosed No No No Comments objects of the issue has changed? Comments Is there any major deviation observed over the No No No Comments earlier monitoring agency reports? Comments Whether all Government/statutory approvals Management No NA No Comments related to the object(s) have been obtained? Undertaking* Comments Whether all arrangements pertaining to technical assistance/collaboration are in NA No Comments Comments operation? Are there any favorable events improving the No No No Comments viability of these object(s)? Comments Are there any unfavorable events affecting the No No No Comments viability of the object(s)? Comments Is there any other relevant information that may materially affect the decision making of the No No Comments Comments investors? NA represents Not Applicable ^ Certificate dated July 31, 2026, issued by M/s Doogar & Associates, Chartered Accountants (Firm Registration Number: 00561N), Statutory auditor of the Company. *The Monitoring Agency has relied solely on the management undertaking as the Statutory Auditor has not expressed an opinion on these aspects. 4) Details of object(s) to be monitored: i. Cost of the object(s): Source of Original Comments of the Board of Directors information/ cost Revised certification (as per the [Showing first 8,000 characters — download PDF for full document]